| Shah, Nirav R |
| Completed | 3 | 300 | US | Anesthetic technique Propofol TIVA, Propofol TIVA, Anesthetic technique inhaled agent, Inhaled agent | Washington University School of Medicine, University of Michigan, University of Pennsylvania, Stanford University, Patient-Centered Outcomes Research Institute | Surgery--Complications, Anesthesia Complication, Anesthesia Awareness, Anesthesia Emergence Delirium, Anesthesia, Surgery, Quality of Life, Pain, Postoperative, Nausea, Postoperative, Anesthesia Morbidity, Depression, Sleep Disorders, Circadian Rhythm | 04/23 | 06/23 | | |
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) |
|
|
| Completed | 3 | 1453 | US | Placebo, Montelukast | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 07/23 | 01/24 | | |
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications |
|
|
| Completed | 3 | 10956 | US | Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 04/24 | 04/24 | | |
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) |
|
|
| Completed | 3 | 3214 | US | Placebo, Metformin | Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center | Covid19 | 06/24 | 11/24 | | |
| Terminated | 3 | 409 | Europe, US, RoW | Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo | Dompé Farmaceutici S.p.A | Infectious Pneumonia, Severe COVID-19 | 09/24 | 09/24 | | |
NCT06666491: An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older |
|
|
| Recruiting | 3 | 300 | RoW | Tafenoquine, Primaquine, Chloroquine | GlaxoSmithKline | Malaria, Vivax | 07/26 | 07/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT04738279: The CASCADE HF Soft Launch and Calibration Phase I and II |
|
|
| Completed | 2/3 | 20 | US | Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring | NorthShore University HealthSystem, physIQ, Inc., Carnegie Mellon University, Northwestern University | Heart Failure | 10/21 | 10/21 | | |
| Completed | 2/3 | 125 | Canada, US | LAU-7b, fenretinide, Placebo oral capsule | Laurent Pharmaceuticals Inc. | COVID-19 Disease | 02/24 | 05/24 | | |
| Recruiting | 2 | 380 | US | IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care | Kanecia Obie Zimmerman | Long COVID, Long Covid19, Long Covid-19 | 12/25 | 03/26 | | |
| Active, not recruiting | 2 | 964 | US | Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control | Kanecia Obie Zimmerman | Long COVID, Long Covid19 | 08/24 | 03/25 | | |
| Active, not recruiting | 2 | 26 | US | Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Prednisone, Pegfilgrastim, filgrastim | University of Wisconsin, Madison, Medical College of Wisconsin | Diffuse Large B Cell Lymphoma, DLBCL, Cancer | 02/25 | 02/27 | | |
NCT06594939: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma |
|
|
| Not yet recruiting | 2 | 31 | US | Polatuzumab Vedotin, Polivy, Mosunetuzumab, Lunsumio, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Prednisone, Pegfilgrastim, filgrastim | Medical College of Wisconsin | Diffuse Large B Cell Lymphoma (DLBCL) | 06/28 | 12/29 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 123 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |
NCT05202782: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma |
|
|
| Active, not recruiting | 2 | 24 | US | Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB | Northwestern University, National Cancer Institute (NCI) | Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma With IRF4 Rearrangement, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma | 10/26 | 10/29 | | |
| Recruiting | 1/2 | 100 | US | 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells | Medical College of Wisconsin | Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma | 01/25 | 01/25 | | |
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
|
|
| Recruiting | 1/2 | 320 | Canada, US | JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax | Juno Therapeutics, a Subsidiary of Celgene | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic | 11/27 | 11/27 | | |
|
|
|
|
|
| Recruiting | 1/2 | 225 | Europe, Japan, US, RoW | Rapcabtagene autoleucel single agent, Ibrutinib | Novartis Pharmaceuticals | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | 06/27 | 05/28 | | |
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL |
|
|
| Recruiting | 1 | 129 | US, RoW | Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine | Imugene Limited | Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | 06/25 | 06/27 | | |
NCT04283097: Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects |
|
|
| Recruiting | 1 | 30 | US | KPG-818, KPG-818 capsules | Kangpu Biopharmaceuticals, Ltd. | Hematological Malignancies | 10/24 | 05/25 | | |
NCT05990465: LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies |
|
|
| Not yet recruiting | 1 | 12 | NA | Pirtobrutinib, Jaypirca, LOXO-305, LV20.19 CAR T cells | Medical College of Wisconsin | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma | 07/26 | 07/27 | | |
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies |
|
|
| Terminated | 1 | 4 | US | 0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells | Medical College of Wisconsin, Miltenyi Biotec, Inc. | B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | 01/24 | 01/24 | | |
| Recruiting | 1 | 120 | US | Docirbrutinib, AS-1763 | Carna Biosciences, Inc. | B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma | 09/27 | 09/27 | | |
| Completed | N/A | 43 | US | Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring | NorthShore University HealthSystem | Heart Failure | 03/23 | 09/23 | | |
| Completed | N/A | 18 | US | Automated health education using a digital health pathway | NorthShore University HealthSystem | Type 2 Diabetes | 11/23 | 12/23 | | |
| Completed | N/A | 11 | US | Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring | NorthShore University HealthSystem | Ileostomy; Complications, Ileostomy - Stoma | 05/22 | 08/22 | | |
| Recruiting | N/A | 660 | US | Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care | Duke University, National Heart, Lung, and Blood Institute (NHLBI) | Long COVID, Long Covid19, Long Covid-19 | 10/25 | 01/26 | | |
SODA, NCT03771508: Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments |
|
|
| Recruiting | N/A | 8000 | US | | Medtronic - MITG | Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp | 12/25 | 12/25 | | |
NCT03375619: Long-term Follow-up Study of Patients Receiving CAR-T Cells |
|
|
| Recruiting | N/A | 500 | US | Long-Term Follow-Up of Participants who Received CAR-T cells | Medical College of Wisconsin | Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma | 01/35 | 01/35 | | |
| Zhang, Yan |
NCT05291650: Ultrasound-guided Injection of Glucocorticoid Into Infrapatellar Fat Pad in Patients With Knee Osteoarthritis |
|
|
| Completed | 4 | 60 | RoW | Glucocorticoids, Saline, Hyaluronic acid | Zhujiang Hospital | Osteoarthritis, Knee | 09/23 | 12/23 | | |
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 1072 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast | 12/27 | 07/28 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
| Active, not recruiting | 3 | 453 | Europe, US, RoW | MRTX849, adagrasib, KRAZATI, Docetaxel, Taxotere | Mirati Therapeutics Inc., Mirati Therapeutics, Inc. | Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | 12/23 | 12/24 | | |
|
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT02159820: Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer |
|
|
| Recruiting | 2/3 | 500 | RoW | Decitabine (DTC Arm), Paclitaxel and Carboplatin (TC Arm) | Chinese PLA General Hospital | Primary Malignant Neoplasm of Ovary, FIGO Stages II to IV | 06/24 | 06/24 | | |
EVEREST, NCT06531161: EleVation carE: a Randomized Controlled Trial on the Prevention of Acute Mountain Sickness With Suxiao Jiuxin Pill |
|
|
| Not yet recruiting | 2/3 | 168 | NA | Suxiao Jiuxin Pill, Placebo | Peking University First Hospital, Tibet Autonomous Region Hospital of Traditional Tibetan Medicine | Acute Mountain Sickness | 09/24 | 09/25 | | |
NCT03989336: A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
|
|
| Completed | 2 | 84 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Platinum chemotherapy, Sintilimab, anti-PD-1 antibody; PD-1 inhibitor | Chinese PLA General Hospital | Ovarian Cancer | 05/22 | 12/23 | | |
NCT03250962: SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 280 | RoW | SHR-1210, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 07/22 | 03/25 | | |
LEAD, NCT05092412: Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC |
|
|
| Active, not recruiting | 2 | 30 | RoW | Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin | You Lu, AstraZeneca | Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab | 02/23 | 06/25 | | |
| Recruiting | 2 | 30 | RoW | Polatuzumab Vedotin, Rituximab, Lenalidomide | Yan Zhang, MD, Peking University Third Hospital, Peking University First Hospital, Chinese PLA General Hospital | Diffuse Large B Cell Lymphoma | 10/25 | 10/27 | | |
PUMCH-NHL-013, NCT05390749: Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL |
|
|
| Recruiting | 2 | 50 | RoW | Orelabrutinib, Pomalidomide, Rituximab, Methotrexate | Peking Union Medical College Hospital, Beijing Tiantan Hospital, Sanbo Brain Hospital Capital Medical University | Primary Central Nervous System Lymphoma | 04/24 | 04/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
IMM01-04, NCT05833984: Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas |
|
|
| Recruiting | 1b/2 | 309 | RoW | IMM01, SIRPα Fc, Tislelizumab | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Solid Tumor, Classic Hodgkin Lymphoma | 02/24 | 11/24 | | |
NCT03989310: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 50 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Gemcitabine, anti-PD-1 antibody, Anti-PD-1 monoclonal antibody; PD-1 inhibitor | Chinese PLA General Hospital | Pancreatic Cancer | 05/21 | 03/22 | | |
NCT04588324: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 50 | RoW | SHR2150, Anti-Cancer Agent | Chinese PLA General Hospital | Solid Tumor | 11/21 | 11/22 | | |
NCT04873440: An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma |
|
|
| Recruiting | 1/2 | 10 | RoW | Manganese Chloride, Mn2+, Radiotherapy, Chemo-immunotherapy | Chinese PLA General Hospital | Solid Tumor, Lymphoma | 05/22 | 05/23 | | |
REMLA, NCT04120350: R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty |
|
|
| Recruiting | 1/2 | 47 | RoW | Methotrexate, Rituximab, Lenalidomide | Peking Union Medical College Hospital, Beijing Tiantan Hospital, Xuanwu Hospital, Beijing, Peking University Third Hospital, Beijing Hospital, Peking University First Hospital, Chinese PLA General Hospital | Primary Central Nervous System Lymphoma | 08/22 | 08/24 | | |
NCT05867771: A Study of PM1022 in Patients With Advanced Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1022 | Biotheus Inc. | Advanced Tumors | 04/24 | 04/25 | | |
NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 168 | RoW | SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
NCT06271928: A Multicenter Clinical Study of Yijing Keli in the Treatment of Ovarian Aging |
|
|
| Recruiting | 1 | 100 | RoW | Yijing Keli | Tongji Hospital | Ovarian Aging | 01/24 | 01/25 | | |
NCT04487093: Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer |
|
|
| Recruiting | 1 | 20 | RoW | neoantigen vaccine + EGFR-TKI, neoantigen vaccine + anti-angioge | First Hospital of Shijiazhuang City, Tianjin Hengjia Biotechnology Development co., LTD | Non Small Cell Lung Cancer | 05/22 | 12/22 | | |
NCT06256783: A Clinical Study of Baozhu Keli in the Treatment of Ovarian Aging |
|
|
| Recruiting | 1 | 100 | RoW | Baozhu Keli | Tongji Hospital | Ovarian Aging | 01/24 | 01/25 | | |
| Recruiting | 1 | 132 | Japan, RoW | SHR-A2009 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/23 | 12/24 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 155 | Canada, US, RoW | YL211 | MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche | Advanced Solid Tumors | 04/27 | 04/29 | | |
| Completed | N/A | 70 | RoW | Plasma exchange (PE), intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP) | Xuanwu Hospital, Beijing | Autoimmune Encephalitis | 12/22 | 09/24 | | |
NCT03703284: Molecular Mechanisms of Malignant Cerebral Edema After LHI |
|
|
| Recruiting | N/A | 120 | RoW | Treatments to reduce intracranial pressure | Xuanwu Hospital, Beijing | Cerebral Edema | 12/22 | 06/23 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
NCT05447572: FIT Combining FC for Predicting MH and Histology Remission in UC |
|
|
| Recruiting | N/A | 300 | RoW | FIT + FC | Shandong University | Ulcerative Colitis, Histology Remission, Fecal Calprotetin, FIT, Mucosal Healing | 12/22 | 12/23 | | |
NCT04361357: The Effects of Enteral Whey Protein Supplement on Serum Albumin Level in Acute Critically Ill Neurological Patients |
|
|
| Recruiting | N/A | 116 | RoW | whey protein | Xuanwu Hospital, Beijing | Nutrition Disorders, Neurologic Disorder | 12/22 | 12/22 | | |
NCT05840861: Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders |
|
|
| Recruiting | N/A | 59 | RoW | Vortioxetine, Quetiapine | Central South University | Major Depressive Disorder, Bipolar Disorder | 08/23 | 09/23 | | |
DELTA, NCT05608655: DKutting Balloon Versus Chocolate Balloon to Treat Femoral and Popliteal Artery Stenosis |
|
|
| Completed | N/A | 188 | RoW | DKutting LL balloon, Chocolate balloon | DK Medical Technology (Suzhou) Co., Ltd. | Femoral Artery Stenosis, Popliteal Artery Stenosis | 01/24 | 02/24 | | |
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH |
|
|
| Recruiting | N/A | 190 | RoW | Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations | Xiangya Hospital of Central South University | Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage | 12/24 | 03/25 | | |
NCT06130319: Correlation of Disease Management and Quality of Life in Patients With Chronic Heart Failure and Their Family Caregivers |
|
|
| Recruiting | N/A | 278 | RoW | | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Chronic Heart Failure | 06/24 | 06/24 | | |
| Not yet recruiting | N/A | 768 | RoW | early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP) | The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital | Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis | 03/26 | 03/26 | | |
NCT06452173: Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis |
|
|
| Enrolling by invitation | N/A | 300 | RoW | Plasma, carotid high-resolution magnetic resonance imaging | Beijing Tiantan Hospital, Beijing Neurosurgical Institute | Carotid Stenosis | 10/26 | 12/26 | | |
NCT06606509: The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). |
|
|
| Not yet recruiting | N/A | 1000 | RoW | Continuous Glucose Monitoring System (GX-01S) | Nanjing First Hospital, Nanjing Medical University | Type1 Diabetes Mellitus | 10/26 | 06/27 | | |
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Observational study, no intervention | Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University | Acute Stroke | 10/22 | 10/23 | | |
| Wei, Wang |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
NCT05342233: Comparison of Conservative and Endovascular Treatment for Spontaneously Isolated Superior Mesenteric Artery Dissection |
|
|
| Recruiting | N/A | 200 | RoW | | Xiangya Hospital of Central South University, The First Medical Center of Chinese PLA General Hospital, West China Hospital, Renmin Hospital of Wuhan University, Peking University Shenzhen Hospital, Affiliated Hospital of Chengde Medical University, Second Affiliated Hospital of Nanchang University, Henan Provincial People's Hospital, The Affiliated Hospital of Inner Mongolia Medical University | Spontaneous Isolated Superior Mesenteric Artery Dissection | 04/27 | 04/28 | | |
| Zhang, Jin li |
NCT03359694: Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer |
|
|
| Not yet recruiting | 3 | 300 | RoW | DT group, Pegylated liposomal doxorubicin and Docetaxel, ET group, Conventional doxorubicin and Docetaxel, NX group, Navelbine and Xeloda | Tianjin Medical University Cancer Institute and Hospital | Susceptibility, Genetic, Chemotherapy Effect | 11/19 | 10/22 | | |
NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. |
|
|
| Completed | 3 | 517 | RoW | Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery | Qilu Pharmaceutical Co., Ltd. | Breast Cancer | 08/22 | 10/23 | | |
CLOVER, NCT03926091: Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer |
|
|
| Recruiting | 3 | 2172 | RoW | Docetaxel, docetaxel injection, Cyclophosphamide, Cyclophosphamide injection | Fudan University | Breast Cancer | 11/24 | 11/25 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer |
|
|
| Recruiting | 3 | 844 | RoW | Tamoxifen, Tamoxifen citrate, Toremifene, fareston | Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University | Breast Cancer Female | 12/25 | 12/25 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
NCT03955978: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer |
|
|
| Active, not recruiting | 1 | 10 | US | TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response | Washington University School of Medicine, Tesaro, Inc. | Endometrial Cancer, Cancer of the Endometrium | 03/24 | 12/25 | | |
| Not yet recruiting | N/A | 402 | NA | S-ketamine, esketamine, normal saline, physiological saline | Beijing Obstetrics and Gynecology Hospital, China Health Promotion Foundation, Beijing Haidian Maternal and Child Health Hospital, Obstetrics & Gynecology Hospital of Fudan University, Fourth Hospital of Shijiazhuang City, Changzhi Maternal and Child Health Hospital, Linfen Maternity&Child Healthcare Hospital, Maternal and Child Health Hospital, Jiading District, Tongzhou Maternal and Child Healthcare Hospital of Beijing, Beijing Chaoyang District Maternal and Child Health Care Hospital | Anesthesia, Analgesia, Depression, Cesarean Section, Parturition | 12/21 | 07/22 | | |
NCT04940091: Epidural Analgesia and Maternal Fever During Labor |
|
|
| Recruiting | N/A | 780 | RoW | Epidural analgesia, No other intervention | Peking University First Hospital, Guangdong Women and Children Hospital, Tangshan Maternal and Child Health Hospital, Dongguan Maternal and Child Health Hospital, Beijing Haidian Maternal and Child Health Hospital, Beijing Fuxing Hospital, Fourth Hospital of Shijiazhuang City, Xiamen Maternity & Child Care Hospital | Epidural Analgesia, Analgesic Effect, Fever | 09/22 | 10/22 | | |
NCT04582955: Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy |
|
|
| Recruiting | N/A | 20 | RoW | Chidamide in combination with chemotherapy, Other Name: For Chidamide: HBI-8000, CS055 | Tianjin Medical University Cancer Institute and Hospital | Triple-negative Breast Cancer | 12/22 | 12/22 | | |
NCT02506361: Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer |
|
|
| Recruiting | N/A | 800 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 05/25 | 10/25 | | |
NCT05534854: Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes |
|
|
| Recruiting | N/A | 500 | RoW | Gene test | RenJi Hospital, Ruijin Hospital, Shanghai Zhongshan Hospital, Huashan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Zhejiang Provincial People's Hospital, Tongji Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Peking University First Hospital | Renal Tumor Histology, Kidney Cancer, Renal Cell Carcinoma, Familial Renal Cancer, HLRCC, VHL Syndrome, BAP1 Tumor Predisposition Syndrome, FLCN Gene Mutation, ALK Gene Mutation, FH Gene Mutation, Birt-Hogg-Dube Syndrome, MET Gene Mutation, Cutaneous Leiomyoma, Cutaneous Leiomyomata With Uterine Leiomyomata | 08/25 | 08/25 | | |
| Wang, Ping H |
NCT03708042: A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer |
|
|
| Not yet recruiting | 3 | 220 | NA | Definitive Radiochemotherapy, Neoadjuvant Radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen University, Peking University Cancer Hospital & Institute | Stage II Esophageal Cancer, Stage III Esophageal Cancer | 12/21 | 12/23 | | |
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC |
|
|
| Not yet recruiting | 3 | 166 | RoW | Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/21 | 10/23 | | |
ACROSS2, NCT04500717: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation |
|
|
| Not yet recruiting | 3 | 460 | RoW | Almonertinib, Aleime, Almonertinib plus carboplatin and pemetrexed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 10/22 | 10/23 | | |
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy | Nanobiotix, Nanobiotix SA | Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | 06/26 | 06/27 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
NCT06798207: A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced |
|
|
| Not yet recruiting | 2 | 90 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gynecological Tumors | 05/26 | 11/26 | | |
NCT04968730: Establishment and Application of Early Postoperative Activity Plan for Patients After Hemi-laminectomy for Lumbar Spinal Tumor Resection |
|
|
| Recruiting | N/A | 100 | RoW | Postoperative rehabilitation nursing | Second Affiliated Hospital, School of Medicine, Zhejiang University | Tumor of Spinal Cord | 12/22 | 12/22 | | |
NCT06686134: Comprehensive Clinical Evaluation Study of GLP-1RA |
|
|
| Recruiting | N/A | 492 | RoW | | LI YAN | T2DM | 12/25 | 07/26 | | |
